Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  

Retrospective Analyses of VIBATIV (telavancin) in Osteomyelitis Patients and in vitro Potency in Challenging Pathogens


TOUR Results Highlight Clinical Response Rates for VIBATIV® (telavancin) in a Range of Difficult-to-Treat Infections; Real-World Use of Antibiotic Observed in Approved Indications, as well as Bone and Joint Infections and Bacteremia

DUBLIN , Oct. 27, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today announced the pricing of concurrent underwritten public offerings of 3,850,000 ordinary shares (the "Shares") at a price to the public of $26.00 per share and $200
DUBLIN , Oct. 26, 2016 /PRNewswire/ -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) (" Theravance Biopharma " or the "Company") today announced that it intends to commence concurrent underwritten public offerings, subject to market and other conditions, of $100 million of its ordinary shares (the

Study Findings Consistent with Single-Ascending Dose (SAD) Data, Demonstrating Sustained Target Engagement, Low Levels of Renal Elimination, Favorable Safety and Tolerability Profile

Revefenacin Meets Primary Efficacy Endpoint and is Shown to be Well-Tolerated in Both Studies; Twelve-Month Safety Trial Ongoing and Targeted for Completion in 2017

First Presentation of TOUR Data Highlights Real World Experience with VIBATIV in Range of Difficult-to-Treat Infections; Additional VIBATIV Presentations Report Results from Retrospective Analysis in Osteomyelitis Patients and Multiple Studies Evaluating in vitro Potency in Challenging Pathogens Compared to Other Commercialized Antibiotics

DUBLIN, IRELAND -- (Marketwired) -- 10/06/16 -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) ("Theravance Biopharma" or the "Company") announced today that stock options to purchase an aggregate of 13,350 of the Company's ordinary shares were granted to five new non-executive officer employees on

Intestinally Restricted Pan-Janus Kinase (JAK) Inhibitor Designed to Act Directly at Site of Inflammation in the Intestinal Wall With Minimal Systemic Exposure

DUBLIN, IRELAND -- (Marketwired) -- 09/07/16 -- Theravance Biopharma, Inc. ( NASDAQ : TBPH) Statistically Significant Benefits in Lung Function, Health-Related Quality of Life and Annual Rate of Exacerbations Observed for Closed Triple as Compared to Symbicort ® Turbohaler ® Theravance